发明授权
- 专利标题： IGF-1 FUSION POLYPEPTIDES AND THERAPEUTIC USES THEREOF
- 专利标题（中）： IGF-1融合多肽和治疗用途
-
申请号： EP06717668.5申请日： 2006-01-06
-
公开(公告)号： EP1833847B1公开(公告)日： 2011-07-20
- 发明人: GLASS, David, J. , YANCOPOULOS, George, D. , DALY, Thomas, J. , PAPADOPOULOS, Nicholas, J.
- 申请人： REGENERON PHARMACEUTICALS, INC.
- 申请人地址： 777 Old Saw Mill River Road Tarrytown, NY 10591 US
- 专利权人： REGENERON PHARMACEUTICALS, INC.
- 当前专利权人： REGENERON PHARMACEUTICALS, INC.
- 当前专利权人地址： 777 Old Saw Mill River Road Tarrytown, NY 10591 US
- 代理机构： Bentham, Andrew
- 优先权： US642229P 20050107; US656583P 20050225
- 国际公布： WO2006074390 20060713
- 主分类号： C07K14/65
- IPC分类号： C07K14/65 ; C07K19/00 ; A61K38/29 ; A61P21/00 ; A61P3/10
摘要：
A fusion protein comprising at least one IGF1 variant component and a fusion component (F), and, optionally, a signal sequence, exhibiting improved stability relative to the native IGF1 or IGF2 polypeptide. The fusion component (F) may be a multimerizing component, a targeting ligand, or another active or therapeutic compound. IGF1 variants were shown to have improved ability to induce skeletal muscle hypertrophy relative to native IGF1.
公开/授权文献
信息查询
